Mandate

Vinge advises Ellevio on acquisition of Elektra Nät and Helsinge Elhandel

Vinge has acted for Ellevio in connection with its acquisition of the shares in Elektra Nät AB, an electricity distribution network operator, and AB Helsinge Elhandel, an energy supplier, from AB Edsbyns Elverk (publ).

The sale is conditional on e.g. approval from the extraordinary shareholders meeting of Edsbyns Elverk and closing is expected to take place on 4 January 2021. In parallel with Ellevio’s acquisition, Edsbyns Elverk has also recommended the extraordinary shareholders meeting to approve a sale of the group’s hydro power business to Fröslida Kraft KB as well as a sale of the electricity installation company Elektra i Hälsingland AB to Kraftkonsult i Skandinavien AB.

Ellevio is one of Sweden’s biggest distribution network operators with ca. 960,000 customers and 500 employees. Ellevio is owned by Tredje AP fonden, Folksam, Första AP fonden and OMERS Infrastructure.

Vinge’s team comprised partner in charge Peter Sundgren (Energy/M&A) and associates Michaela Cronemyr (M&A) and Oliviva Belding (M&A), partner David Andersson (Capital markets and Public M&A) and associate Ludvig Frithiof (Capital markets and Public M&A), partner Johan Cederblad (Environmental law/Real Estate) and associates Kristoffer Larson (Real Estate), Olof Löfvenberg (Environmental law/Real Estate), Karl-Hugo Engdahl (Corporate Commercial), Sara Strandberg (Employment) and Lisa Ullman (Employment).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026